Daré to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license...
ORION CORPORATION PRESS RELEASE 4 July 2023 at 12.00 EEST Orion publishes Half-Year Financial Report for January–June 2023 on Monday...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES...
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American:...
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks...
CLEVELAND, July 03, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has raised $25 million...
YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for...
VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional...
-- Ready-to-dilute, multi-dose vials reduce compounding time and waste -- BRIDGEWATER, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Nevakar Injectables...
SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that...
Company completes spin-off from Labcorp and begins trading on Nasdaq under ticker “FTRE” Independent company positioned to capitalize on growth...
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab...
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on...
Madrigal expects to complete full submission of the New Drug Application in July 2023CONSHOHOCKEN, Pa., June 30, 2023 (GLOBE NEWSWIRE)...
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the...
Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readoutIRVINE, Calif.,...
- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling...
EO4010 uniquely mimics five distinct tumor-associated antigens designed to provide multi-targeted, broad tumor coverage, maximizing tumor killing and preventing immune...
MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Highlights key initiatives that will drive the company’s transition towards a more sustainable businessReaffirms commitment to environmentally and socially responsible...